Phagocytic synapse enhancers are developed, a class of modular immune engagers comprising a high-affinity PD-L1 binder coupled to a macrophage-stimulating peptide, tuftsin, that provides a blueprint for a plug-and-play platform of immune engagers targeting diverse cancer-associated pathways.
Valerio Sabatino, Cong Tang, Rita C. Acúrcio et al.· Cancer Research· 0 citations
Glioblastoma (GBM) is the most aggressive primary brain tumour and is frequently accompanied by severe neurological symptoms, including epilepsy and cognitive impairment. Neurological symptoms often persist after surgical resection, indicating that GBM induces durable and self-sustaining changes in the surrounding neur...
Giulia Amos, Luc Jordi, K. Ahuja et al.· bioRxiv· 0 citations
Glioblastoma remains one of the most aggressive primary brain tumors in adults, with a survival rarely exceeding 15 months despite multimodal therapy. Novel immunotherapeutic strategies, particularly chimeric antigen receptor T-cell therapy, have emerged as promising approaches to overcome the limitations of convention...
M. Etter, K. Akeret, Raphael Guzman et al.· CNS Drugs· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
